文献速递胸部CT

无症状人群低剂量胸部CT中人工智能辅助肺结节评估:一项前瞻性随机对照试验

Artificial Intelligence-Assisted Lung Nodule Evaluation on Low-Dose Chest CT in Asymptomatic Individuals: A Prospective Randomized Controlled Trial.
PubMed 文献 · AJR Am J Roentgenol · 2026-03-18

该前瞻性单中心随机对照试验纳入911例无症状体检者,比较AI辅助与无AI辅助解读低剂量CT的解读时间和结节检出率。AI辅助组与对照组的解读时间无显著差异(187秒 vs 172秒,p=.23),但AI辅助组Lung-RADS阳性结节检出率(16.9% vs 10.3%,p=.03)、所有结节检出率(52.9% vs 32.6%,p=.002)及随访LDCT推荐频率(15.3% vs 7.4%,p=.04)均显著更高。两组均无肺癌诊断。

要点

  • AI辅助未显著延长解读时间(187秒 vs 172秒,p=.23)。
  • AI辅助显著提高Lung-RADS阳性结节检出率(16.9% vs 10.3%,p=.03)。
  • AI辅助显著提高所有结节检出率及随访LDCT推荐频率。

核心结论

  • 将AI结节评估工具整合入PACS实际工作流程未显著改变解读时间,但与临床可操作结节检出率显著提高相关。

研究设计与样本

  • 前瞻性单中心平行开放标签随机对照试验,纳入2025年5月19日至2025年9月4日连续无症状体检者911例(男517例,女394例;平均年龄62岁;干预组447例,对照组464例),1:1随机分配至AI辅助解读组或无AI辅助解读组,由10名胸部放射科医生之一解读,仅报告≥4 mm结节。

诊断标准与关键数值

  • AI工具自动检测、分类和测量结节,结果在PACS内显示。
  • Lung-RADS阳性定义为类别3或4。
  • 仅报告直径≥4 mm的结节。
  • 干预组Lung-RADS阳性结节检出率16.9% vs 对照组10.3%(p=.03)。
  • 干预组所有结节检出率52.9% vs 对照组32.6%(p=.002)。

临床应用与阅片要点

  • AI辅助解读可提高Lung-RADS阳性结节及所有结节的检出率,并增加随访LDCT推荐频率。
  • AI辅助解读未显著增加单次检查解读时间。
  • 本研究仅报告≥4 mm结节,AI工具在实际工作流程中整合于PACS。

局限性

  • 研究为单中心设计。
  • 随访时间中位数干预组215天、对照组216天,不足以评估肺癌诊断结局。
  • 两组均无个体诊断为肺癌。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. The impact of artificial intelligence (AI) tools for lung nodule evaluation on low-dose CT (LDCT) has been evaluated primarily using experimental retrospective reader designs, outside of clinical practice. OBJECTIVE. The purpose of this study was to compare interpretation times and lung nodule detection rates between real-world interpretations conducted with versus without an AI-based lung nodule evaluation tool for LDCT examinations in asymptomatic individuals. METHODS. This prospective single-center, parallel, open-label clinical trial included consecutive individuals who underwent LDCT of the chest during a self-initiated general health checkup from May 19, 2025, to September 4, 2025. Individuals underwent 1:1 random allocation to an intervention (AI-assisted interpretation) or control (interpretation without AI) group. In the intervention group, a commercial AI tool automatically detected, classified, and measured nodules, and the results were displayed within PACS. Examinations were interpreted by one of 10 thoracic radiologists, who reported only nodules that measured at least 4 mm. The primary outcome was interpretation time per examination. Secondary outcomes included the detection rates (proportion of examinations reporting a finding) of Lung-RADS-positive (category 3 or 4) nodules and of all nodules and the frequency of recommendations for follow-up LDCT. Subsequent lung cancer diagnoses were recorded. RESULTS. The final analysis included 911 individuals (517 men, 394 women; mean age, 62 years; 447 and 464 in the intervention and control groups, respectively). The intervention group, in comparison with the control group, showed no significant difference in interpretation time per examination (187 vs 172 seconds, respectively; p = .23) but a significantly higher detection rate of Lung-RADS-positive nodules (16.9% vs 10.3%, respectively; p = .03), detection rate of all nodules (52.9% vs 32.6%, respectively; p = .002), and frequency of follow-up LDCT recommendations (15.3% vs 7.4%, respectively; p = .04). No individual in either group was diagnosed with lung cancer (median follow-up of 215 and 216 days in intervention and control groups, respectively). CONCLUSION. Use of an AI-based nodule evaluation tool integrated into PACS during real-world clinical workflows was not associated with a significant difference in interpretation times. However, the tool was associated with significantly greater detection of clinically actionable nodules. CLINICAL IMPACT. This randomized clinical trial provides pragmatic evidence regarding the implications of AI-assisted LDCT interpretation. TRIAL REGISTRATION. Clinical Research Information Service KCT0010206.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Hwang EJ, Lee T, Lim WH, et al. Artificial Intelligence-Assisted Lung Nodule Evaluation on Low-Dose Chest CT in Asymptomatic Individuals: A Prospective Randomized Controlled Trial. AJR Am J Roentgenol. 2026. PMID: 41848489. doi:10.2214/AJR.26.34552

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。